About this Research Topic
Many patients experience cancer recurrence and metastasis several years or even decades after they have had radical surgery. This phenomenon can be interpreted as cancer dormancy, a period in cancer progression in which residual disease exists, but remains indiscernible or clinically asymptomatic for long periods. Tumor dormancy was first defined as early as 1934 by Rupert Willis and then redefined by Geoffrey Hadfield in 1954 as a temporary arrest in mitosis and growth. Thus far, substantial quantities of publications have found three primary potential models that can be put forth to explain the process of dormancy, including angiogenic dormancy, immunologic dormancy, and cellular dormancy. The dynamics of cancer dormancy have been implicated in the recurrence and metastasis of cancer patients.
In this Research Topic, we welcome manuscripts addressing the following themes:
• Pathological issues in, and the definition of, cancer dormancy
• EMT and cancer dormancy
• Cancer stem cells and dormancy
• Environment and cancer dormancy
• Signaling pathways of cancer dormancy
• Models of cancer dormancy
• Clinical management of cancer dormancy
Keywords: EMT, cancer stem cells, dormancy, invasion, metastasis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.